natgillin/translations-raw huggingface dataset:
Before beginning treatment: To reduce the risk of liver injury you should not use Tasmar if you have a liver disease in case of elevated liver function tests in the blood test done before starting treatment (tests of alanine amino transferase (ALT) and aspartate amino transferase (AST)). 
Kako bi se smanjio rizik od oštećenja jetre, ne biste smjeli uzimati Tasmar - ako imate bolest jetre - u slučaju povišenih jetrenih funkcija u krvnom nalazu učinjenom prije početka liječenja (testovi alanin aminotransferaze (ALT) i aspartat aminotransferaze (AST)).
If you do not get better at the higher dose after a total of 3 weeks, your doctor should stop your treatment with Tasmar. 
Ako Vam ne bude bolje nakon ukupno 3 tjedna pri većoj dozi, Vaš liječnik bi trebao prekinuti liječenje Tasmarom.
Administered concomitantly with levodopa and an aromatic amino acid decarboxylase inhibitor (AADC-I), it leads to more stable plasma levels of levodopa by reducing metabolism of levodopa to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD). 
Primijenjen istodobno s levodopom i inhibitorom dekarboksilaze aromatske aminokiseline (AADC-I), dovodi do stabilnijih razina levodope u plazmi reducirajući metabolizam levodope na 3-metoksi-4hidroksi-L-fenilalanin (3-OMD).
Effect of tolcapone on the metabolism of other drugs: Due to its affinity for cytochrome CYP2C9 in vitro, tolcapone may interfere with drugs whose clearance is dependent on this metabolic pathway, such as tolbutamide and warfarin. 
Učinak tolkapona na metabolizam drugih lijekova: zbog njegova afiniteta za citokrom CYP2C9 in vitro, tolkapon može međudjelovati s lijekovima čiji je klirens ovisan o tom metaboličkom putu, kao što su tolbutamid i varfarin.
Patients being treated with Levodopa and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see also section 
Bolesnici koji se liječe levodopom i razviju somnolenciju i/ili epizode iznenadnog sna moraju biti informirani da se suzdržavaju od upravljanja vozilima ili upuštanja u aktivnosti u kojima bi oštećena pozornost mogla predstavljati rizik od ozbiljne ozljede ili smrti za njih ili za druge osobe (npr. rad na strojevima) sve dok takve ponavljajuće epizode i somnolencija ne prestanu (vidjeti također dio 4.4).
There is no evidence from clinical studies that Tasmar adversely influences a patient's ability to drive and use machines. 
Nema dokaza iz kliničkih ispitivanja da Tasmar štetno utječe na bolesnikovu sposobnost upravljanja vozilima i rada sa strojevima.
Neuroleptic Malignant Syndrome (NMS): 
NMS (neuroleptički maligni sindrom):
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. 
Bolesnici koji su iskusili somnolenciju i/ili epizodu iznenadnog nastupa sna moraju se suzdržati od upravljanja vozilima ili rada na strojevima.
On the other hand, after co-administration of tolcapone and benserazide-50 mg/levodopa the benserazide plasma concentrations could be increased above the levels usually observed with levodopa/benserazide alone. 
S druge strane, nakon istodobne primjene tolkapona i benzerazida-50 mg/levodope, koncentracije benzerazida u plazmi mogu se povećati iznad razina uobičajeno opaženih samo s levodopom/benzerazidom.
The recommended dose of Tasmar is 100 mg three times daily, always as an adjunct to levodopa/benserazide or levodopa/carbidopa therapy. 
Preporučena doza Tasmara je 100 mg tri puta dnevno, uvijek kao adjuvantna terapija levodopi/benzerazidu ili levodopi/karbidopi.
In animal studies, tolcapone was excreted into maternal milk. 
U ispitivanjima na životinjama tolkapon se izlučivao u majčino mlijeko.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU I UNUTRAŠNJEM PAKIRANJU
Patients with hepatic impairment (see section 4.3) Tasmar is contraindicated for patients with liver disease or increased liver enzymes. 
Bolesnici s oštećenjem jetre (vidjeti dio 4.3) Tasmar je kontraindiciran u bolesnika s bolešću jetre ili povišenim jetrenim enzimima.
Summary of potentially Tasmar-related adverse reactions, with crude incidence rates for the phase III placebo-controlled studies: 
Sažetak nuspojava potencijalno povezanih s Tasmarom s grubim stopama učestalosti iz faze 3 placebom kontroliranih ispitivanja:
Since Tasmar should be used only in combination with levodopa/benserazide and levodopa/carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar. 
Budući da se Tasmar smije primjenjivati samo u kombinaciji s levodopom/benzerazidom i levodopom/karbidopom, informacije o propisivanju ovih pripravaka levodope su također primjenjive na njihovu istodobnu primjenu s Tasmarom.
Therefore, you should contact your doctor immediately if you experience symptoms such as nausea, vomiting, pain in your stomach (particulary over the liver in the right upper area), loss of appetite, weakness, fever, darkening of urine, jaundice (yellow skin or eyes) or if you tire more easily. 
Stoga se trebate odmah obratiti liječniku ako iskusite simptome kao što su mučnina, povraćanje, bol u želucu (osobito kod jetre u gornjem desnom području), gubitak apetita, slabost, vrućica, tamnija mokraća, žutica (žuta koža ili oči) ili ako se lakše umorite.
if you have a special type of tumor in the adrenal medulla (Phaeochromocytoma) - if you take a certain medication to treat depression and anxiety, called non-selective mono amino oxidase (MAO) inhibitors 
- ako imate posebnu vrstu tumora u srži nadbubrežne žlijezde (feokromocitom) - ako uzimate određene lijekove za liječenje depresije i tjeskobe, koji se zovu neselektivni inhibitori monoaminooksidaze (MAO).
To improve efficacy, your doctor should only increase the dose to the higher dose (200 mg three times a day) if the increase in how your Parkinson's disease symptoms are controlled outweighs the expected increase in side effects. 
Kako bi poboljšao učinkovitost Vaš liječnik smije dozu povećati na veću dozu (200 mg tri puta dnevno), samo ako poboljšanje u kontroliranju simptoma Parkinsonove bolesti nadjačava očekivano pojačanje nuspojava.
NMS is characterised by motor symptoms (rigidity, myoclonus and tremor), mental status changes (agitation, confusion, stupor and coma), elevated temperature, autonomic dysfunction (labile blood pressure, tachycardia) and elevated serum creatine phosphokinase (CPK) which may be a consequence of myolysis. 
NMS je karakteriziran motoričkim simptomima (rigidnost, mioklonus i tremor), promjenama mentalnog statusa (agitacija, konfuzija, stupor i koma), povišenom temperaturom, autonomnom disfunkcijom (labilni krvni tlak, tahikardija) i povišenom serumskom kreatin fosfokinazom (engl. creatine phosphokinase, (CPK), koja može biti posljedica miolize.
In clinical trials, patients receiving Tasmar/levodopa preparations reported a similar adverse reaction profile independent of whether or not they were also concomitantly administered selegiline (a MAO-B inhibitor). 
U kliničkim ispitivanjima bolesnici koji su primali Tasmar/pripravke levodope prijavili su nuspojave sličnog profila neovisno o tome jesu li ili nisu istodobno uzimali selegilin (MAO-B inhibitor).
The administration of Tasmar is restricted to prescription and supervision by physicians experienced in the management of advanced Parkinson's disease. 
Primjena Tasmara ograničena je na propisivanje i nadzor liječnika iskusnih u zbrinjavanju uznapredovale Parkinsonove bolesti.
If you have missed several doses, please inform your doctor and follow the advice given to you 
Ako ste propustili nekoliko doza, obavijestite svog liječnika te primijenite savjet koji ste dobili.
However, when Tasmar therapy is being discontinued for reasons other than too much levodopa, levodopa dose may have to be increased to levels equal to or greater than before initiation of Tasmar therapy, especially if the patient had large decreases in levodopa when starting Tasmar. 
Međutim, kada se prekida terapija Tasmarom zbog drugih razloga osim previše levodope, doza levodope će se možda morati povećati do razina jednakih ili većih od onih prije početka terapije Tasmarom, osobito ako je bolesnik imao velika smanjenja doze levodope pri početku liječenja Tasmarom.
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines (see section 4.7). 
Bolesnici koji su iskusili somnolenciju i/ili epizodu iznenadnog nastupa sna moraju se suzdržati od upravljanja vozilima ili rada na strojevima (vidjeti dio 4.7).
Hypokinesia Syncope 
često hipokinezija sinkopa
Contact your doctor, pharmacist or hospital immediately as you may need urgent medical attention. 
Vaš lijek, odmah se obratite liječniku ili bolnici jer će njoj ili njemu možda biti potrebna hitna medicinska pomoć.
When beginning Tasmar, all patients should be informed of the symptoms of excessive levodopa dose and what to do if it occurs. 
Kad počinju liječenje Tasmarom svi bi bolesnici morali biti informirani o simptomima prevelike doze levodope te što činiti ako do toga dođe.
Overall, the frequency of adverse reactions increased slightly. 
U cjelini, učestalost nuspojava povećala se neznatno.
Tolcapone is a low-extraction-ratio drug (extraction ratio = 0.15), with a moderate systemic clearance of about 7 L/h. 
Tolkapon je lijek s niskim omjerom ekstrakcije (omjer ekstrakcije = 0,15), s umjerenim sistemskim klirensom od otprilike 7 l/h.
Drugs that increase catecholamines: Since tolcapone interferes with the metabolism of catecholamines, interactions with other drugs affecting catecholamine levels are theoretically possible. 
Lijekovi koji povisuju kateholamine: budući da tolkapon međudjeluje s metabolizmom kateholamina, teoretski su moguće interakcije s drugim lijekovima koji utječu na razine kateholamina.
If you forget to take Tasmar 
Ako ste zaboravili uzeti Tasmar
Tasmar therapy should only be initiated by physicians experienced in the management of advanced Parkinson's disease, to ensure an appropriate risk-benefit assessment. 
Terapiju Tasmarom trebaju započeti jedino liječnici iskusnici u zbrinjavanju uznapredovale Parkinsonove bolesti, kako bi osigurali odgovarajuću procjenu rizika i koristi.
This could be explained by the fact that only a negligible amount of unchanged tolcapone is excreted in the urine, and the main metabolite, tolcapone-glucuronide, is excreted both in urine and in bile (faeces). 
To se može objasniti činjenicom da se samo zanemariva količina nepromijenjenog tolkapona izlučuje u urinu te da se glavni metabolit, tolkapon-glukuronid, izlučuje i putem urina i žuči (feces).
Therefore, caution should be exercised when potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered to Parkinson's disease patients being treated with Tasmar and levodopa preparations. 
Stoga treba biti oprezan kada se snažni inhibitori pohrane noradrenalina kao što su desipramin, maprotilin ili venlafaksin daju bolesnicima s Parkinsonovom bolešću koji se liječe Tasmarom i pripravcima levodope.
An increased incidence of uterine adenocarcinomas was seen in the high-dose group of the rat carcinogenicity study. 
Opažena je povećana učestalost adenokarcinoma maternice u skupini štakora koja je primala visoke doze u ispitivanja kancerogenosti.
A study in patients with hepatic impairment has shown that moderate non-cirrhotic liver disease had no impact on the pharmacokinetics of tolcapone. 
Ispitivanje bolesnika s oštećenjem jetre pokazalo je da umjerena necirotična bolest jetre nema utjecaja na farmakokinetiku tolkapona.
Patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine. 
Bolesnici s nasljednim problemima intolerancije galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze-galaktoze ne bi smjeli uzimati ovaj lijek.
Please inform your doctor about all other medicines you are taking especially: antidepressants, alpha-methyldopa (used to treat increased blood pressure), apomorphine (used for Parkinson's disease), dobutamine (used for the chronic heart disease), adrenaline and isoprenaline (both used for heart attacks) anticoagulants of the warfarin type (that prevent blood clotting). 
Obavijestite svog liječnika o svim lijekovima koje uzimate, osobito ako su to: - antidepresivi, - alfa-metildopa (koristi se za liječenje povišenog krvnog tlaka), - apomorfin (koristi se za Parkinsonovu bolest), - dobutamin (koristi se za kroničnu bolest srca), - adrenalin i izoprenalin (oboje se koriste za srčane udare), - antikoagulansi varfarinskog tipa (koji sprječavaju zgrušavanje krvi).
The only adverse reaction commonly leading to discontinuation of Tasmar in clinical trials was diarrhoea (see section 4.4). 
Jedina nuspojava koja je obično vodila do prekida liječenja Tasmarom u kliničkim ispitivanjima bio je proljev (vidjeti dio 4.4).
No information on the tolerability of tolcapone in these populations is available (see section 5.2). 
Nisu dostupni podaci o podnošljivosti tolkapona u ovim populacijama (vidjeti dio 5.2).
MAO inhibitors: Tasmar should not be given in conjunction with non-selective monoamine oxidase (MAO) inhibitors (e.g. phenelzine and tranylcypromine). 
MAO inhibitori: Tasmar se ne smije davati zajedno s neselektivnim inhibirotima monoaminooksidaze (MAO) (npr. fenelzin i tranilcipromin).
How to take Tasmar 
Kako uzimati Tasmar
The peak plasma concentrations of tolcapone at this dose were on average 30 µg/ml (compared to 3 and 6 µg/ml with 100 mg tid and 200 mg tid of tolcapone respectively). 
Vršne koncentracije tolkapona u plazmi pri ovoj dozi bile su prosječno 30 µg/ml (u usporedbi s 3 i 6 µg/ml sa 100 mg tolkapona tri puta dnevno, odnosno 200 mg tolkapona tri puta dnevno).
In addition, rhabdomyolysis, secondary to NMS or severe dyskinesia, has been observed. 
Uz to, opažene su rabdomioliza sekundarna NMS-u ili teška diskinezija.
Treatment with non-selective mono amino oxidase (MAO) inhibitors 
• Liječenje neselektivnim inhibitorima monoaminoksidaze (MAO)
Tasmar can be combined with all pharmaceutical formulations of levodopa/benserazide and levodopa/carbidopa (see also section 4.5). 
Tasmar se može kombinirati sa svim farmaceutskim oblicima levodope/benzerazida i levodope/karbidope (vidjeti također dio 4.5).
Review of treatment is recommended if such symptoms develop. 
Ako se razviju takvi simptomi, preporučuje se ponovno razmatranje liječenja.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose malabsorption should not take this medicine. 
Bolesnici s rijetkim nasljednim problemima intolerancije galaktoze, nedostatka Lapp laktaze ili malapsorpcije glukoze ne bi smjeli uzimati ovaj lijek.
Evidence of liver disease or increased liver enzymes Severe dyskinesia 
• Dokazi o bolesti jetre ili povišeni jetreni enzimi
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments such as Tasmar in association with levodopa. 
Bolesnici i njegovatelji trebaju biti svjesni da bihevioralni simptomi poremećaja kontrole impulsa uključujući patološko kockanje, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu se javiti u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim liječenjima kao što je Tasmar u kombinaciji s levodopom.
This means when it is taken together with levodopa (as levodopa/benserazide or levodopa/carbidopa) you should have an improvement in the symptoms of your Parkinson's disease. 
To znači da biste tijekom uzimanja ovog lijeka zajedno s levodopom (kao levodopa/benzerazid ili levodopa/karbidopa) trebali iskusiti poboljašanje simptoma Parkinsonove bolesti.
Hypersensitivity to tolcapone or any of its other ingredients listed in section 6.1. 
• Preosjetljivost na tolkapon ili neku od pomoćnih tavri navedenih u dijelu 6.1.
Date of first authorisation: 27 August 1997 Renewal of the authorisation: 31 August 2004 Date of latest renewal: 21 July 2014 
Datum posljednje obnove: 21. srpanj 2014.
Treatment should be immediately discontinued if ALT and/or AST exceed the upper limit of normal or if symptoms or signs suggesting the onset of hepatic failure (persistent nausea, fatigue, lethargy, anorexia, jaundice, dark urine, pruritus, right upper quadrant tenderness) develop. 
Liječenje treba odmah prekinuti ako ALT i/ili AST premaše gornju granicu normale ili se razviju simptomi ili znakovi koji upućuju na nastup zatajenja jetre (dugotrajna mučnina, umor, letargija, anoreksija, žutica, tamni urin, pruritus, osjetljivost gornjeg desnog kvadranta).
1 film-coated tablet Tasmar 
1 filmom obložena tableta Tasmar
The plasma concentrations of benserazide observed after co-administration of tolcapone and benserazide-25 mg/levodopa were still within the range of values observed with levodopa/benserazide alone. 
Koncentracije benzerazida u plazmi opažene nakon istodobne primjene tolkapona i benzerazida25 mg/levodope bile su još uvijek unutar raspona vrijednosti opaženih samo s levodopom/benzerazidom.
While receiving treatment: During treatment, blood tests will be done in the following time intervals: every 2 weeks during the first 12 months of therapy, every 4 weeks during the following 6 months of therapy, every 8 weeks during further treatment. 
Tijekom liječenja će krvni testovi biti učinjeni u sljedećim vremenskim razmacima: - svaka 2 tjedna tijekom prvih 12 mjeseci terapije, - svaka 4 tjedna tijekom sljedećih 6 mjeseci terapije, - svakih 8 tjedana tijekom daljnjeg liječenja.
Dyskinesia, nausea and other levodopa-associated adverse reactions: Patients may experience an increase in levodopa-associated adverse reactions. 
Diskinezija, mučnina i druge nuspojave povezane s levodopom: bolesnici mogu iskusiti povećanje nuspojava povezanih s levodopom.
Patients with renal impairment (see section 5.2) 
Bolesnici s oštećenjem bubrega (vidjeti dio 5.2)
“TASMAR” and “100” are engraved on one side. 
“TASMAR” i “100” su ugravirani na jednoj strani.
30 film-coated tablets 60 film-coated tablets 100 film-coated tablets 200 film-coated tablets 
30 filmom obloženih tableta 60 filmom obloženih tableta 100 filmom obloženih tableta 200 filmom obloženih tableta
The most commonly observed adverse reactions associated with the use of Tasmar, occurring more frequently than in placebo-treated patients are listed in the table below. 
Najčešće opažene nuspojave povezane s primjenom Tasmara koje su se javljale češće nego u bolesnika koji su primali placebo navedene su u tablici ispod.
Renal impairment: The pharmacokinetics of tolcapone have not been investigated in patients with renal impairment. 
Oštećenje bubrega: farmakokinetika tolkapona nije istražena u bolesnika s oštećenjem bubrega.
The prescriber should be observant of adverse reactions caused by putative increased plasma levels of these drugs when combined with Tasmar. 
Liječnikkoji propisuje lijek treba pozorno pratiti moguće nuspojave prouzročenih putativnim povećanjem plazmatskih razina ovih lijekova kada se uzimaju istodobno s Tasmarom.
Increase of alanine aminotransferase (ALT) 
Pretrage često povećanje alanin aminotransferaze (ALT)
Orange yellow to brown yellow, hexagonal, biconvex, film-coated tablet. 
Narančasto žuta do smeđe žuta, heksagonalna, bikonveksna, filmom obložena tableta.
No information on the tolerability of tolcapone in these populations is available (see section 5.2) 
Nisu dostupni podaci o podnošljivosti tolkapona u ovim populacijama (vidjeti dio 5.2)
Film-coat: Hydroxypropylmethylcellulose, Talc, Yellow iron oxide, Ethylcellulose, Titanium dioxide, Triacetin, Sodium lauril sulfate. 
Film ovojnica: hidroksipropilmetilceluloza, talk, žuti željezov oksid, etilceluloza, titanijev dioksid, triacetin, natrijev laurilsulfat.
o 
I
During treatment: Liver function should be monitored every 2 weeks for the first year of therapy, every 4 weeks for the next 6 months and every 8 weeks thereafter. 
Tijekom liječenja: funkciju jetre treba nadzirati svaka 2 tjedna tijekom prve godine terapije, svaka 4 tjedna tijekom sljedećih 6 mjeseci te svakih 8 tjedana nakon toga.
“TASMAR” and “200” are engraved on one side. 
“TASMAR” i “200” su ugravirani na jednoj strani.
Increases to more than three times the upper limit of normal (ULN) in alanine aminotransferase (ALT)occurred in 1 % of patients receiving Tasmar 100 mg three times daily, and 3 % of patients at 200 mg three times daily. 
Povećanja na više od tri puta od gornje granice normale (GGN) u alanin aminotransferazi (ALT) javila su se u 1 % bolesnika koji su primali Tasmar 100 mg tri puta dnevno i 3 % bolesnika koji su primali 200 mg tri puta dnevno.
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, 4.2) 
Lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2)
The consequent increase in dopaminergic stimulation can lead to the dopaminergic adverse reactions observed after treatment with COMT inhibitors. 
Posljedično povećanje dopaminergičke stimulacije može voditi do dopaminergičkih nuspojava opaženih nakon liječenja COMT inhibitorima.
severe symptoms of muscle stiffening, fever or mental confusion (Neuroleptic Malignant Syndrome) when antiparkinsonian treatments are abruptly reduced or withdrawn - Impulse control disorders (inability to resist the impulse of an action that could be harmful). 
Rijetko: - teški simptomi ukočenosti mišića, vrućica ili mentalna smetenost (neuroleptički maligni sindrom) kada se liječenje lijekovima za Parkinsonovu bolest naglo smanji ili ukine - poremećaj kontrole impulsa (nemogućnost odupiranja impulsu za neki postupak koji može biti štetan)
Tolcapone's effect on levodopa pharmacokinetics is similar with all pharmaceutical formulations of levodopa/benserazide and levodopa/carbidopa; it is independent of levodopa dose, levodopa/AADC-I (benserazide or carbidopa) ratio and the use of sustained-release formulations. 
Učinak tolkapona na farmakokinetiku levodope sličan je kod svih farmaceutskih oblika levodope/benzerazida i levodope/karbidope; neovisan je o dozi levodope, omjeru levodope/AADC-I (benzerazid ili karbidopa) te primjeni oblika s produljenim oslobađanjem.
Neuroleptic Malignant Syndrome Symptom Complex 
Grupa simptoma neuroleptičkog malignog sindroma
Special populations: Patients with severe renal impairment (creatinine clearance <30 ml/min) should be treated with caution. 
Posebne populacije: bolesnike s teškim oštećenjem jetre (klirens kreatinina <30 ml/min) treba liječiti s oprezom.
The data of more than 400 patients have confirmed that over a wide range of creatinine clearance values (30-130 mL/min) the pharmacokinetics of tolcapone are unaffected by renal function. 
Podaci o više od 400 bolesnika potvrdili su da bubrežna funkcija ne utječe na farmakokinetiku tolkapona kroz široki raspon vrijednosti klirensa kreatinina (30130 ml/min).
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed (non-prescription medicines and herbals). 
Obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli bilo koje druge lijekove, uključujući i one koji nisu propisani (bezreceptne i biljne lijekove).
Diarrhoea: In clinical trials, diarrhoea developed in 16 % and 18 % of patients receiving Tasmar 100 mg tid and 200 mg tid respectively, compared to 8 % of patients receiving placebo. 
Proljev: u kliničkim ispitivanjima, proljev je razvilo 16 % i 18 % bolesnika koji su uzimali Tasmar 100 mg tri puta dnevno, odnosno 200 mg tri puta dnevno, u usporedbi s 8 % bolesnika koji su primali placebo.